166 related articles for article (PubMed ID: 21771722)
1. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Tang L; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Kristal AR; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JK; Santella RM; Hsing A; Hoque A; Lippman SM; Thompson IM; Ambrosone CB
Carcinogenesis; 2011 Oct; 32(10):1500-6. PubMed ID: 21771722
[TBL] [Abstract][Full Text] [Related]
2. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
[TBL] [Abstract][Full Text] [Related]
4. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; Tang L; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Thompson IM; Ambrosone CB; Hoque A
Cancer Causes Control; 2011 Aug; 22(8):1121-31. PubMed ID: 21667068
[TBL] [Abstract][Full Text] [Related]
5. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry.
Brureau L; Moningo D; Emeville E; Ferdinand S; Punga A; Lufuma S; Blanchet P; Romana M; Multigner L
PLoS One; 2016; 11(4):e0153609. PubMed ID: 27074016
[TBL] [Abstract][Full Text] [Related]
7. Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.
Black A; Pinsky PF; Grubb RL; Falk RT; Hsing AW; Chu L; Meyer T; Veenstra TD; Xu X; Yu K; Ziegler RG; Brinton LA; Hoover RN; Cook MB
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2374-82. PubMed ID: 25178985
[TBL] [Abstract][Full Text] [Related]
8. Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta.
Douglas JA; Zuhlke KA; Beebe-Dimmer J; Levin AM; Gruber SB; Wood DP; Cooney KA
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2035-9. PubMed ID: 16103457
[TBL] [Abstract][Full Text] [Related]
9. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men.
Karatzas A; Giannatou E; Tzortzis V; Gravas S; Aravantinos E; Moutzouris G; Melekos M; Tsezou A
Cancer Epidemiol; 2010 Jun; 34(3):345-9. PubMed ID: 20308029
[TBL] [Abstract][Full Text] [Related]
11. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
Modugno F; Weissfeld JL; Trump DL; Zmuda JM; Shea P; Cauley JA; Ferrell RE
Clin Cancer Res; 2001 Oct; 7(10):3092-6. PubMed ID: 11595700
[TBL] [Abstract][Full Text] [Related]
12. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.
Schenk JM; Till C; Hsing AW; Stanczyk FZ; Gong Z; Neuhouser ML; Reichardt JK; Hoque AM; Figg WD; Goodman PJ; Tangen CM; Thompson IM
Cancer Causes Control; 2016 Feb; 27(2):175-82. PubMed ID: 26589415
[TBL] [Abstract][Full Text] [Related]
13. Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial.
Gong Z; Platek ME; Till C; Goodman PJ; Tangen CM; Platz EA; Neuhouser ML; Thompson IM; Santella RM; Ambrosone CB
Front Oncol; 2021; 11():808715. PubMed ID: 35096612
[TBL] [Abstract][Full Text] [Related]
14. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Neuhouser ML; Till C; Kristal A; Goodman P; Hoque A; Platz EA; Hsing AW; Albanes D; Parnes HL; Pollak M
Cancer Prev Res (Phila); 2010 Mar; 3(3):279-89. PubMed ID: 20179296
[TBL] [Abstract][Full Text] [Related]
15. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
Cussenot O; Azzouzi AR; Nicolaiew N; Fromont G; Mangin P; Cormier L; Fournier G; Valeri A; Larre S; Thibault F; Giordanella JP; Pouchard M; Zheng Y; Hamdy FC; Cox A; Cancel-Tassin G
J Clin Oncol; 2007 Aug; 25(24):3596-602. PubMed ID: 17704407
[TBL] [Abstract][Full Text] [Related]
16. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
[TBL] [Abstract][Full Text] [Related]
17. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk.
Deming SL; Zheng W; Xu WH; Cai Q; Ruan Z; Xiang YB; Shu XO
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):563-70. PubMed ID: 18349273
[TBL] [Abstract][Full Text] [Related]
18. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.
Sparks R; Ulrich CM; Bigler J; Tworoger SS; Yasui Y; Rajan KB; Porter P; Stanczyk FZ; Ballard-Barbash R; Yuan X; Lin MG; McVarish L; Aiello EJ; McTiernan A
Breast Cancer Res; 2004; 6(5):R488-98. PubMed ID: 15318931
[TBL] [Abstract][Full Text] [Related]
19. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Chau CH; Price DK; Till C; Goodman PJ; Chen X; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Tangen CM; Chu L; Parnes HL; Schenk JM; Reichardt JK; Thompson IM; Figg WD
PLoS One; 2015; 10(5):e0126672. PubMed ID: 25955319
[TBL] [Abstract][Full Text] [Related]
20. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
